Search results for "Drug withdrawal"

showing 10 items of 15 documents

Adverse drug reactions in the oral cavity

2012

Several drugs may have a number of adverse reactions (ADRs) involving the oro-facial region. The dose of the drug and the time required for the reaction to take place are relevant parameters; nonetheless, ADRs mechanisms are not always known and ADRs are not always predictable since aspects other than drug pharmacodynamics and/or pharmacokinetics, as well as various interacting variables contribute to the final outcome. All tissues and many functions of the oral cavity can be affected. In particular, salivary function is fre- quently involved and hypo-salivation is the main manifestation; several mucosal lesions with different morphology (ulcerations, vesiculo- bullous lesions, white lesion…

Drugdrug pharmacodynamicosteonecrosimedicine.medical_specialtyTime FactorsDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjectSettore MED/50 - Scienze Tecniche Mediche Applicatehypo-salivationPigmentationsPharmacologyOral cavitymucosal lesionDrug withdrawalPharmacokineticsSettore MED/28 - Malattie OdontostomatologicheDrug DiscoveryHumansMedicinemedical liabilityDrug reactionpharmacokineticmedia_commonPharmacologyMouthDose-Response Relationship Drugbusiness.industrybisphosphonates.Mucosal lesionsMouth MucosadrugAdverse reactionmedicine.diseaseDermatologyPharmaceutical PreparationsTastePharmacodynamicsoral cavityadverse drug reaction oral cavityMouth DiseasesSalivationbusiness
researchProduct

Drug‐refractory myasthenia gravis: Clinical characteristics, treatments, and outcome

2022

[Objective] To describe the clinical characteristics and outcomes in patients with refractory myasthenia gravis (MG) and to determine the effectiveness and side effects of the drugs used for their treatment.

Maleprogressive multifocal leukoencepdiarrheacholinergic receptorplasma exchangemiddle agedadultimmunologic factornauseaanemiahypertrichosisageddrug withdrawaldiabetes mellitusdisease severityTRIALsafetycorticosteroidhypertensionImmunologyMiastenia gravismethotrexateArticlebulbar paralysispancytopeniaMuscular DiseasescompulsionMyasthenia Gravischolinesterase inhibitorcross-sectional studyHumansImmunologic FactorshumanRITUXIMABarthralgiaNeurologíaMalalties muscularsAgedRetrospective Studiesmyasthenia gravisleukopeniaabdominal painDrug testingmajor clinical studyCross-Sectional StudiesDrug side effectscyclophosphamideobservational studyNeurology (clinical)immunoglobulinFEATURESefficacyclinical outcomeelectrophysiological procedurescomputer assisted tomographyDOUBLE-BLINDTratamiento médicorituximabOutcome Assessment Health CareImmunologiamuscle specific tyrosine kinaseRegistriestacrolimusazathioprineMedicamentoGeneral Neurosciencenephrotoxicitygeneral condition deteriorationhyperplasiatrialMiddle Agedliver toxicitydrug toxicityunclassified drugfemaleEfectes secundaris dels medicamentsSAFETYFemaledouble-blindheadacheblindnessAdultAssaigs clínics de medicamentsmalefeaturesfollow uppneumoniacyclosporinemycophenolate mofetilprotein tyrosine kinaseimmunosuppressive agentallergyalopeciaEFFICACYclinical featureosteopeniaSpainprednisonehyperglycemiaautoantibodyFollow-Up Studies
researchProduct

Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm…

2020

Background and objectives: Current psoriasis guidelines do not usually include recommendations about first line classical or biologic treatment. The objectives of this study were: to describe shifts in the prescription of the first biological treatment, and to compare treatment withdrawal and rates of adverse events over ten years. Material and methods: Biobadaderm registry was analyzed to describe: first biological prescription in bio-naive patients, adverse events rate and reasons for drug withdrawal comparing three periods of time (2008-2010, 2011-2014, 2015-2018). Results: Anti-TNF drugs were the most prescribed biological drug from 2008 to 2010. Ustekinumab has become the most prescrib…

Drugmedicine.medical_specialtyHistologyBiologicmedia_common.quotation_subjectDiscontinuationDermatologyBiologic treatmentPathology and Forensic Medicine030207 dermatology & venereal diseases03 medical and health sciencesDrug withdrawal0302 clinical medicinePsoriasisUstekinumabTrendmedicinePsoriasisMedical prescriptionIntensive care medicineAdverse effectmedia_commonbusiness.industryBiobadadermmedicine.diseaseDiscontinuationTreatment030220 oncology & carcinogenesisbusinessmedicine.drug
researchProduct

Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal

2011

OBJECTIVE To examine the impact of withdrawing rosiglitazone and ramipril medication on diabetes incidence after closeout of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. RESEARCH DESIGN AND METHODS The 3,366 DREAM subjects at trial end who had not developed diabetes while taking double-blind study medication were transferred to single-blind placebo for 2 to 3 months before undergoing an oral glucose tolerance test. Glycemic status was analyzed for the trial plus washout period and for the washout period alone. RESULTS Following median (interquartile range) 71 (63–86) days drug withdrawal, overall glycemic status remained modestly improved in t…

RamiprilAdultMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolism030204 cardiovascular system & hematologyPlaceboRosiglitazone03 medical and health sciencesDrug withdrawal0302 clinical medicineRamiprilInterquartile rangeInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsGlycemicOriginal ResearchAdvanced and Specialized Nursingbusiness.industryIncidence (epidemiology)IncidenceClinical Care/Education/Nutrition/Psychosocial ResearchMiddle Agedmedicine.disease3. Good healthSurgerySubstance Withdrawal SyndromeTreatment OutcomeDiabetes Mellitus Type 2FemaleThiazolidinedionesRosiglitazonebusinessmedicine.drugFollow-Up StudiesDiabetes Care
researchProduct

Prophylaxis of hemicrania continua: two new cases effectively treated with topiramate.

2007

Hemicrania continua (HC) is an uncommon and under-recognized primary headache disorder characterized by a strictly unilateral continuous headache of moderate intensity with possible exacerbations and associated with ipsilateral autonomic features. HC has generally a prompt and enduring response to indomethacin although 25% to 50% of treated patients develop gastrointestinal side effects. These cases pose a difficult management challenge as no other drug is consistently effective in HC. Recently 2 HC patients responsive to topiramate treatment have been reported. Here we describe 2 more patients effectively treated with topiramate. Neither reported any side effects and one had persisting res…

DrugTopiramateAdultmedia_common.quotation_subjectmedicine.medical_treatmentIndomethacinNeurological disorderFructoseCentral nervous system diseaseDrug withdrawalPrimary headacheTopiramateProfilaxismedicineHumansmedia_commonbusiness.industryAnti-Inflammatory Agents Non-SteroidalHeadacheHemicrania continuaMiddle Agedmedicine.diseaseAnticonvulsantNeurologyHemicrania continuaAnesthesiaGastritisRetreatmentSettore MED/26 - NeurologiaAnticonvulsantsFemaleNeurology (clinical)businessmedicine.drugHeadache
researchProduct

Optimizing diagnostic approach to drug-induced liver injury

2018

Drug-induced liver injury (DILI) is often a trial even to expert clinicians, because sometimes diagnosis is not easy to be made. Guidelines of the American College of Gastroenterology (ACG) yielded in 2014, help to better understand the problem. The diagnosis of DILI is made through a detailed evaluation of clinical, serological, radiological and histological aspects. Biochemical data include liver function tests that allow to assess the pattern of damage, such as hepatocellular, cholestatic and mixed liver injury; serological data include testing for major and possibly minor hepatotropic viruses, non-organ specific autoantibodies. Clinical scenario might include jaundice, nausea, vomiting …

medicine.medical_specialtySettore MED/09 - Medicina InternaDrug-induced liver injurydiagnosisclinical approach.lcsh:MedicineClinical approach03 medical and health sciencesDrug withdrawalLiver disease0302 clinical medicinemedicineEosinophiliaLiver injurymedicine.diagnostic_testbusiness.industryMedicine (all)lcsh:RGeneral MedicineJaundicemedicine.disease030220 oncology & carcinogenesisLiver biopsy030211 gastroenterology & hepatologyRadiologymedicine.symptomTransient elastographybusinessLiver function testsDiagnosiItalian Journal of Medicine
researchProduct

Nationwide evaluation of day-to-day clinical pharmacists' interventions in German hospitals.

2015

tudy Objective To describe and evaluate the extent and diversity of nationwide data from clinical pharmacists’ interventions (PIs) in German hospitals. Design Retrospective analysis. Data Source The ADKA-DokuPIK German database, a national anonymous self-reported Internet-based documentation system for routine PIs as well as for medication errors reported by German hospital pharmacists. Measurements and Main Results Data sets from ADKA-DokuPIK entered between January 2009 and December 2012 were analyzed descriptively. A total of 27,610 PIs were entered, mainly by ward-based clinical pharmacists (82.5%). Most of the PIs were performed on surgical wards (37.8%), followed by anesthesiology/int…

Data sourcemedicine.medical_specialtyDatabases Factualbusiness.industryPsychological interventionIntensive care unitlanguage.human_languagelaw.inventionGermanClinical pharmacySafety-Based Drug WithdrawalslawAnesthesiologyGermanyAntithromboticEmergency medicinemedicinelanguageAdverse Drug Reaction Reporting SystemsHumansMedication ErrorsPharmacology (medical)Day to daybusinessPharmacy Service HospitalPharmacotherapy
researchProduct

Psychomotor and Motor Speed in Power Athletes Self-Administering Testosterone and Anabolic Steroids

1988

Abstract The effect of self-administered testosterone and anabolic steroids on psychomotor and motor speed were studied among five top-level power athletes. The experiment included a 26-week intensive strength training period in association with the use of exogenous hormones and a 6-week follow-up after drug withdrawal. Six athletes not using exogenous hormones served as a control group. The results indicated a similar, and in most cases insignificant, improvement (0–10%) in performance in both groups in both the simple and more complicated motor and psychomotor tests. Only in maximal vertical speed related to body weight was there more improvement in the experimental group, from 122.2 to 1…

Psychomotor learningmedicine.medical_specialtyAnabolismbiologyAthletesStrength trainingPhysical Therapy Sports Therapy and RehabilitationGeneral Medicinemedicine.diseasePhysical strengthbiology.organism_classificationDrug withdrawalEndocrinologyNephrologyInternal medicinemedicineOrthopedics and Sports MedicineMotor speedPsychologyTestosteroneResearch Quarterly for Exercise and Sport
researchProduct

Mpdz is a quantitative trait gene for drug withdrawal seizures

2004

Physiological dependence and associated withdrawal episodes can constitute a powerful motivational force that perpetuates drug use and abuse. Using robust behavioral models of drug physiological dependence in mice, positional cloning, and sequence and expression analyses, we identified an addiction-relevant quantitative trait gene, Mpdz. Our findings provide a framework to define the protein interactions and neural circuit by which this gene's product (multiple PDZ domain protein) affects drug dependence, withdrawal and relapse.

DrugGenotypePositional cloningmedia_common.quotation_subjectMolecular Sequence DataQuantitative Trait LociPDZ domainGene ExpressionQuantitative trait locusBiologyProtein–protein interactionMiceMice CongenicDrug withdrawalSeizuresmedicineAnimalsGenetic Predisposition to DiseaseCloning MolecularGenemedia_commonGeneticsBehavior AnimalEthanolGeneral NeuroscienceChromosome MappingMembrane ProteinsEmbryo Mammalianmedicine.diseaseSubstance Withdrawal SyndromeMice Inbred C57BLCarrier ProteinsNeuroscienceNature Neuroscience
researchProduct

Delayed effects of ciprofibrate on rat liver peroxisomal properties and proto-oncogene expression.

1995

Peroxisome proliferators (PPs) are non-genotoxic carcinogens in rodents. Their reversible effects on rat liver have been studied with ciprofibrate and fenofibrate. We found that with the hypolipemic drug fenofibrate a pause of 28 days is sufficient for a return to normal status, whereas with the highly potent PP ciprofibrate, the stimulation of ACO mRNA levels remains after its withdrawal. We investigated the effects of the renewal of the treatment with PPs on other peroxisomal parameters and proto-oncogene expression using Wistar rats. Interestingly, c-myc expression was enhanced even upon drug withdrawal, and was more stimulated by the second exposure to ciprofibrate, while c-fos expressi…

Malemedicine.medical_specialtyTime FactorseducationStimulationMitochondria LiverBiologyBiochemistryMicrobodiesDrug withdrawalClofibric AcidFenofibrateInternal medicineProto-Oncogene ProteinsGene expressionmedicineAnimalsRats WistarCarcinogenPharmacologyFenofibrateOncogeneFibric AcidsPeroxisomemedicine.diseaseRatsEndocrinologyLiverMicrosomes LiverCiprofibrateAcyl-CoA OxidaseOxidoreductasesmedicine.drugBiochemical pharmacology
researchProduct